The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
Drug-induced thrombotic microangiopathy (DITMA) is a secondary cause of thrombotic microangiopathy and a potentially fatal inflammatory disease. DITMA has been attributed to a variety of drugs, particularly chemotherapeutic and immunosuppressive agents. Prompt diagnosis is critical for survival and...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Libro |
| Pubblicazione: |
SAGE Publishing,
2020-08-01T00:00:00Z.
|
| Soggetti: | |
| Accesso online: | Connect to this object online. |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_65f89a54ac954d14b4ab079c08e1621d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Jihad Ben Gabr MD |e author |
| 700 | 1 | 0 | |a Hiba Bilal MD |e author |
| 700 | 1 | 0 | |a Kanish Mirchia MD |e author |
| 700 | 1 | 0 | |a Andras Perl MD, PhD |e author |
| 245 | 0 | 0 | |a The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy |
| 260 | |b SAGE Publishing, |c 2020-08-01T00:00:00Z. | ||
| 500 | |a 2324-7096 | ||
| 500 | |a 10.1177/2324709620947266 | ||
| 520 | |a Drug-induced thrombotic microangiopathy (DITMA) is a secondary cause of thrombotic microangiopathy and a potentially fatal inflammatory disease. DITMA has been attributed to a variety of drugs, particularly chemotherapeutic and immunosuppressive agents. Prompt diagnosis is critical for survival and treatment necessitates withdrawal of the offending drug; however, many cases require further treatment including plasmapheresis, immunosuppression, and anticoagulation. In this article, we report a cutaneous biopsy-proven case of tacrolimus-induced DITMA, which was successfully treated with eculizumab after failing the conventional standard of care. | ||
| 546 | |a EN | ||
| 690 | |a Medicine (General) | ||
| 690 | |a R5-920 | ||
| 690 | |a Pathology | ||
| 690 | |a RB1-214 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Investigative Medicine High Impact Case Reports, Vol 8 (2020) | |
| 787 | 0 | |n https://doi.org/10.1177/2324709620947266 | |
| 787 | 0 | |n https://doaj.org/toc/2324-7096 | |
| 856 | 4 | 1 | |u https://doaj.org/article/65f89a54ac954d14b4ab079c08e1621d |z Connect to this object online. |